5 completed. 5 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow Central Retinal Vein Occlusion: new trials by email Literature Review of Central Retinal Vein Occlusion trials Research Report on Central Retinal Vein Occlusion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO) 601 1.25mg, Ranibizuman 0.5 mg - Central Retinal Vein Occlusion | Phase 2 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 60 | 2021-01-27 | 2025-06-27 |
| Treatment of Central Retinal Vein Occlusion Using Stem Cells Study Autologous Bone Marrow CD34+ Stem Cells, Sham Therapy - Central Retinal Vein Occlusion | Phase 1 / Phase 2 | Completed | The Emmes Company, LLC | 16 | 2019-10-22 | 2024-12-02 |
| Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion Intravitreal Aflibercept Injection - Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy | Phase 1 / Phase 2 | Completed | Ophthalmic Consultants of Boston | 24 | 2012-11-01 | 2015-05-22 |
| Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab ranibizumab 0.5mg, ranibizumab 1.0mg - Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion | Phase 1 / Phase 2 | Completed | Hanscom, Thomas, M.D. | 14 | 2011-11-01 | 2015-04-29 |
| The ROVO Study: Radial Optic Neurotomy for CVO Intravitreal Triamcinolone, Radial Optic Neurotomy, Placebo - Sham Intravitreal Injection - Central Retinal Vein Occlusion | Phase 2 / Phase 3 | Completed | Rudolf Foundation Clinic | 2005-04-01 | 2009-10-30 |
Retinal Vein Occlusion (5) · Eye Diseases (1) · Macular Edema (1) · Retinal Diseases (1)
Cardiovascular Diseases (5) · Embolism and Thrombosis (5) · Thrombosis (5) · Vascular Diseases (5) · Venous Thrombosis (5) · Eye Diseases (4) · Retinal Diseases (4) · Macular Degeneration (1) · Retinal Degeneration (1)
Ranibizumab (2)
Hanscom, Thomas, M.D. (1) · Ophthalmic Consultants of Boston (1) · Rudolf Foundation Clinic (1) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (1) · The Emmes Company, LLC (1)
United States (3) · Austria (1) · China (1)
Jeffrey S Heier, MD (1) · Susanna S Park, MD, PhD (1) · Susanne Binder, M.D. (1) · Thomas O'Hearn, MD (1)
1UG1EY026876-01A1 (1), 1UG1EY028517-01 (1)